CSNpharm
SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
sb4
100mg
| ≥98%
CSNpharm
sb4
10mg
| ≥98%
CSNpharm
sb4
25mg
| ≥98%
CSNpharm
sb4
5mg
| ≥98%
CSNpharm
sb4
50mg
| ≥98%
CSNpharm
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases.
More Information
Supplier Page
CSNpharm
SBE-β-CD, a modified cyclodextrin, is designed to optimize the solubility, stability, bioavailability and dosing of drugs.
More Information
Supplier Page
CSNpharm
SBE-β-CD, a modified cyclodextrin, is designed to optimize the solubility, stability, bioavailability and dosing of drugs.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
SC 236
100mg
| ≥99%
CSNpharm
SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.
More Information
Supplier Page
CSNpharm
SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.
More Information
Supplier Page
CSNpharm
SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.
More Information
Supplier Page
CSNpharm
SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.
More Information
Supplier Page
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
SC-560
100mg
| ≥99%
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
CSNpharm
SC-560 is a highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 μM for COX-1 and COX-2 respectively). It inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production and significantly reduces ovarian surface epithelial tumor growth in vivo.
More Information
Supplier Page
SC514
5mg
| ≥99%
CSNpharm
SC514 is a potent, reversible, ATP-competitive and highly selective IKK-β(IKK-2) inhibitor with IC50 value ranging in 3-12 µM.
More Information
Supplier Page
SC514
50mg
| ≥99%
CSNpharm
SC514 is a potent, reversible, ATP-competitive and highly selective IKK-β(IKK-2) inhibitor with IC50 value ranging in 3-12 µM.
More Information
Supplier Page
SC514
10mg
| ≥99%
CSNpharm
SC514 is a potent, reversible, ATP-competitive and highly selective IKK-β(IKK-2) inhibitor with IC50 value ranging in 3-12 µM.
More Information
Supplier Page
SC66
100mg
| ≥99%
CSNpharm
SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.
More Information
Supplier Page
SC66
10mg
| ≥99%
CSNpharm
SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.
More Information
Supplier Page
SC66
5mg
| ≥99%
CSNpharm
SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.
More Information
Supplier Page
SC66
50mg
| ≥99%
CSNpharm
SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.
More Information
Supplier Page
SC66
25mg
| ≥99%
CSNpharm
SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.
More Information
Supplier Page
SC99
10mg
| ≥98%
CSNpharm
SC99
5mg
| ≥98%
CSNpharm
SC99
1mg
| ≥98%
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm